• In combination with ASA, ticagrelor, compared with clopidogrel, reduced the risk of vascular events including total mortality, in NSTEACS patients treated medically, surgically or with PCI
• STEMI patients treated with primary PCI had similar, but not statistically significant benefits
• Non-CABG related major bleeding was increased with ticagrelor
• Increased rates of transient dyspnea and ventricular pauses are observed with use of ticagrelor
• Ticagrelor is contraindicated in patients with history of intracerebral bleeding and should be used with caution in patients with severe bradycardia